ArticleClinical biochemistry2010
Nidogen-2: a new serum biomarker for ovarian cancer.
Article in Clinical biochemistry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Meta-analysis of gene expression signatures defining the epithelial to mesenchymal transition during cancer progression.PloS one · 2012Pooled it
- Evaluation of NID2 and CDO1 methylation for ovarian cancer screening.Oncology letters · 2026Article
- NID2 Affects Prognosis of Glioma via Activating the Akt Signaling Pathway.International journal of molecular sciences · 2025Article
- Proteome analysis of urinary biomarkers in a cigarette smoke-induced COPD rat model.Respiratory research · 2022Article
- Elevated levels of serum nidogen-2 in esophageal squamous cell carcinoma.Cancer biomarkers : section A of Disease markers · 2018Article
- Focused Analysis of Exome Sequencing Data for Rare Germline Mutations in Familial and Sporadic Lung Cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2016Article
- A review on hepatocyte nuclear factor-1beta and tumor.Cell & bioscience · 2015Review
- Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients.Clinical biochemistry · 2013Article
- CGPredictor: a systematic integrated analytic tool for mining and examining genome-scale cancer independent prognostic epigenetic marker panels.BMC systems biology · 2013Article
- Discovery of multi-dimensional modules by integrative analysis of cancer genomic data.Nucleic acids research · 2012Article
- Methylation status of NEUROG2 and NID2 improves the diagnosis of stage I NSCLC.Oncology letters · 2012Article
- Distribution of nidogen in the murine eye and ocular phenotype of the nidogen-1 knockout mouse.ISRN ophthalmology · 2012Article
- Multifunctional core-shell nanoparticles: discovery of previously invisible biomarkers.Journal of the American Chemical Society · 2011Article
- Basement membrane components are key players in specialized extracellular matrices.Cellular and molecular life sciences : CMLS · 2010Review
- Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer.Nature reviews. Cancer · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 3 countries.
Funding
Abstract
objectivesNew ovarian cancer biomarkers suitable for early disease diagnosis, prognosis or monitoring could improve patient management and outcomes. DESIGN AND
methodsNidogen-2 was measured by immunoassay in serum of 100 healthy women, 100 women with benign gynecological conditions and 100 women with ovarian carcinoma.
resultsSerum nidogen-2 concentration between normal and benign disease patients was not different (median, 13.2 and 12.1 mg/L, respectively). However, nidogen-2 concentration in serum of ovarian cancer patients was elevated (median, 18.6 mg/L; p<0.0001). Both nidogen-2 and CA125 were elevated more in serous histotypes of ovarian cancer and late state disease. Nidogen-2 and CA125 concentrations were strongly correlated. ROC curve analysis for nidogen-2 had an area under the curve (AUC) ranging from 0.73 to 0.83 but CA125 was superior (AUC ranging from 0.87 to 0.99). There was no complementarity between the two markers.
conclusionsNidogen-2 is a new biomarker for ovarian cancer which correlates closely with CA125.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.